1117 related articles for article (PubMed ID: 17570225)
21. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma.
Kohga K; Tatsumi T; Takehara T; Tsunematsu H; Shimizu S; Yamamoto M; Sasakawa A; Miyagi T; Hayashi N
J Hepatol; 2010 Jun; 52(6):872-9. PubMed ID: 20395004
[TBL] [Abstract][Full Text] [Related]
22. Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression.
Gambelli F; Sasdelli F; Manini I; Gambarana C; Oliveri G; Miracco C; Sorrentino V
Cell Biol Int; 2012 Jan; 36(1):29-38. PubMed ID: 21916848
[TBL] [Abstract][Full Text] [Related]
23. Inhibitory effects of transcription factor Ikaros on the expression of liver cancer stem cell marker CD133 in hepatocellular carcinoma.
Zhang L; Li H; Ge C; Li M; Zhao FY; Hou HL; Zhu MX; Tian H; Zhang LX; Chen TY; Jiang GP; Xie HY; Cui Y; Yao M; Li JJ
Oncotarget; 2014 Nov; 5(21):10621-35. PubMed ID: 25301737
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X
Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214
[TBL] [Abstract][Full Text] [Related]
25. CD133+ renal progenitor cells contribute to tumor angiogenesis.
Bruno S; Bussolati B; Grange C; Collino F; Graziano ME; Ferrando U; Camussi G
Am J Pathol; 2006 Dec; 169(6):2223-35. PubMed ID: 17148683
[TBL] [Abstract][Full Text] [Related]
26. [Progress and prospects in cancer stem cell research for hepatocellular carcinoma].
Xu W; Cao L; Yin ZF
Ai Zheng; 2009 Sep; 28(9):1004-8. PubMed ID: 19728923
[TBL] [Abstract][Full Text] [Related]
27. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.
Ma S; Lee TK; Zheng BJ; Chan KW; Guan XY
Oncogene; 2008 Mar; 27(12):1749-58. PubMed ID: 17891174
[TBL] [Abstract][Full Text] [Related]
28. Human liver progenitor cell lines are readily established from non-tumorous tissue adjacent to hepatocellular carcinoma.
Zhang A; London R; Schulz FM; Giguère-Simmonds PW; Delriviere L; Chandraratana H; Hardy K; Zheng S; Olynyk JK; Yeoh G
Stem Cells Dev; 2010 Aug; 19(8):1277-84. PubMed ID: 19874130
[TBL] [Abstract][Full Text] [Related]
29. CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells.
Lan X; Wu YZ; Wang Y; Wu FR; Zang CB; Tang C; Cao S; Li SL
Int J Mol Med; 2013 Feb; 31(2):315-24. PubMed ID: 23233126
[TBL] [Abstract][Full Text] [Related]
30. Cord blood CD133 cells define an OV6-positive population that can be differentiated in vitro into engraftable bipotent hepatic progenitors.
Crema A; Ledda M; De Carlo F; Fioretti D; Rinaldi M; Marchese R; Sanchez M; Giuliani M; Arena V; Durrbach A; Brunetti E; Haas C; Ponzetto A; Lisi A; Carloni G
Stem Cells Dev; 2011 Nov; 20(11):2009-21. PubMed ID: 21291316
[TBL] [Abstract][Full Text] [Related]
31. G protein-coupled receptor 87 (GPR87) promotes the growth and metastasis of CD133⁺ cancer stem-like cells in hepatocellular carcinoma.
Yan M; Li H; Zhu M; Zhao F; Zhang L; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
PLoS One; 2013; 8(4):e61056. PubMed ID: 23593389
[TBL] [Abstract][Full Text] [Related]
32. Autophagy contributes to the survival of CD133+ liver cancer stem cells in the hypoxic and nutrient-deprived tumor microenvironment.
Song YJ; Zhang SS; Guo XL; Sun K; Han ZP; Li R; Zhao QD; Deng WJ; Xie XQ; Zhang JW; Wu MC; Wei LX
Cancer Lett; 2013 Oct; 339(1):70-81. PubMed ID: 23879969
[TBL] [Abstract][Full Text] [Related]
33. Regulatory role of miR-142-3p on the functional hepatic cancer stem cell marker CD133.
Chai S; Tong M; Ng KY; Kwan PS; Chan YP; Fung TM; Lee TK; Wong N; Xie D; Yuan YF; Guan XY; Ma S
Oncotarget; 2014 Jul; 5(14):5725-35. PubMed ID: 25015418
[TBL] [Abstract][Full Text] [Related]
34. Active glycolytic metabolism in CD133(+) hepatocellular cancer stem cells: regulation by MIR-122.
Song K; Kwon H; Han C; Zhang J; Dash S; Lim K; Wu T
Oncotarget; 2015 Dec; 6(38):40822-35. PubMed ID: 26506419
[TBL] [Abstract][Full Text] [Related]
35. Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer.
Chen WC; Chang YS; Hsu HP; Yen MC; Huang HL; Cho CY; Wang CY; Weng TY; Lai PT; Chen CS; Lin YJ; Lai MD
Oncotarget; 2015 Dec; 6(40):42923-37. PubMed ID: 26556861
[TBL] [Abstract][Full Text] [Related]
36. Oxytetracycline have the therapeutic efficiency in CD133
Song Y; Kim IK; Choi I; Kim SH; Seo HR
Sci Rep; 2018 Oct; 8(1):16100. PubMed ID: 30382122
[TBL] [Abstract][Full Text] [Related]
37. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma.
Terris B; Cavard C; Perret C
J Hepatol; 2010 Feb; 52(2):280-1. PubMed ID: 20006402
[TBL] [Abstract][Full Text] [Related]
38. CD133 confers cancer stem-like cell properties by stabilizing EGFR-AKT signaling in hepatocellular carcinoma.
Jang JW; Song Y; Kim SH; Kim JS; Kim KM; Choi EK; Kim J; Seo HR
Cancer Lett; 2017 Mar; 389():1-10. PubMed ID: 28034805
[TBL] [Abstract][Full Text] [Related]
39. Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors.
Rutella S; Bonanno G; Procoli A; Mariotti A; Corallo M; Prisco MG; Eramo A; Napoletano C; Gallo D; Perillo A; Nuti M; Pierelli L; Testa U; Scambia G; Ferrandina G
Clin Cancer Res; 2009 Jul; 15(13):4299-311. PubMed ID: 19509143
[TBL] [Abstract][Full Text] [Related]
40. [Preliminary interpretation on the relationship between the phenotype of CD133+ cells and niche in transplanted human glioma in mice].
Song WC; Fei XF; Dong J
Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):564-9. PubMed ID: 21122405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
